LOS ANGELES, March 03, 2020 (GLOBE NEWSWIRE) -- PRESS RELEASE -- OG DNA Genetics, a globally recognized cannabis brand, has announced a licensing agreement with PurePenn LLC, a cultivator and producer of pharmaceutical-grade cannabis capsules, concentrates, tinctures, flower and oils for the Pennsylvania market.
The agreement will grant PurePenn license to the DNA brand, access to its proprietary award-winning genetics and standardized operating procedures for their cultivation at the PurePenn cultivation facility in McKeesport, Penn. PurePenn’s high-tech facility will be comprised of approximately 125,000 square feet of indoor cultivation and production upon completion of its ongoing expansion efforts.
“By partnering with PurePenn, we ensure a mutually beneficial relationship built on the foundation of commitment to quality and best practices,” said Don Morris, co-founder of DNA. “Each time we explore a potential licensing agreement, we look for the best possible partner in each market – PurePenn is that partner for Pennsylvania.”
Dedicated to cutting-edge innovation using the latest technology, highly trained and experienced scientists and operators, and the strictest safety standards, PurePenn's mission is to create the best marijuana-based medicine in Pennsylvania for patients in need.
For more than 15 years, genetics developed by DNA have won more than 200 awards in all categories at the most prestigious cannabis events around the world, making DNA the global standard in breeding and growing truly best-in-class strains. These awards include the High Times ‘Top 10 Strain of the Year’, which was inducted into The High Times seedbank hall of fame in 2009, the High Times 100 list of the most influential people in the industry and the High Times Trailer Blazers Award, for contributions made towards uniting the fields of entrepreneurship, politics and medicine.
“We are very excited by the opportunity to partner with DNA Genetics,” commented Gabe Perlow, CEO of PurePenn. “With our rapidly expanding cultivation facility, combined with their award-winning genetics and procedures, we will continue to provide patients in Pennsylvania with the highest-quality and most sought-after medicine possible."
